Biological agents such as anti-tumor necrosis factor (TNF)-α antibodies have demonstrated efficacy in treating RA; however, their clinical use carries the risk of infusion and injection site infections, and their efficacy may vary depending on the patient’s individual needs (Zhao et al., 2022a). This evidence concerns the gene TNF and infection.